Table 1  Potential anti-COVID-19 therapeutics that are being tested in clinical trials based on targeting the post-entry events of the life cycle of SARS-CoV-2 a.
Viral Polymerase Inhibitors
Remdesivir  Emtricitabine & tenofovir alafenamide
Galidesivir  Favipiravir
Ribavirin  AT-527
Clevudine  EIDD-2801
Emtricitabine & tenofovir disoproxil
Viral protease inhibitors
Lopinavir/ritonavir  Atazanavir
Darunavir/cobicistat  Danoprevir/ritonavir
ASC-09  Maraviroc
Miscellaneous antiviral agents
Selinexor  Levamisole
Nitazoxanide  BLD-2660
NSAIDs (Indomethacin and naproxen) b  N-Acetylcysteine
Vidofludimus  Artesunate
Brequinar  Povidone-iodine solution
Famotidine  Chlorhexidine
VERU-111  Methylene blue
Leflunomide  Inhaled nitric oxide
Sirolimus  Poly-alcohols (Resveratrol & quercetin)
Plitidepsin  Thymalfasin
Cyclosporine  Lactoferrin
Deferoxamine  TY027
Atovaquone  XAV-19
a Some of the listed therapeutics have multiple antiviral mechanisms. Some also have anti-inflammatory effects. b NSAIDs is an acronym for nonsteroidal anti-inflammatory drugs.